Plain-English translation of NCT06502743 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for advanced endometrial cancer that hasn't been treated before (or has come back after prior treatment). The core treatment includes three drugs: , Paclitaxel, and Carboplatin, which are given together in the first phase. Then, some patients will continue with the medication alone, while others will take it combined with a newer drug called to see if the combination works better.
Endometrial cancer that is advanced or has returned after treatment is hard to treat, and doctors are looking for better options. This trial is testing whether adding this newer drug to standard treatment could help more patients respond better and live longer.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of three drugs once every three weeks for 6 cycles (about 18 weeks). After that, you'll enter a maintenance phase where you'll receive longer infusions every six weeks for up to 14 more cycles, and depending on which group you're assigned to, you may also take a daily oral pill. Throughout the study, you'll have regular blood tests and scans to monitor how well the treatment is working and watch for side effects. The entire study could last several months to over a year.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
South Korea